Cosentyx is indicated for the treatment of: moderate to severe plaque psoriasis in adults, adolescents and children from the age of 6 years who are candidates for systemic therapy; active psoriatic arthritis in adult patients, alone or in combination with MTX, when the response to previous DMARD therapy has been inadequate; active ankylosing spondylitis in adults who have responded inadequately to conventional therapy; active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated CRP and/or MRI evidence in adults who have responded inadequately to NSAIDs.
Hear more from other professionals around the UK on how they are using You First in real-life clinical practice
You First: The benefits of a bespoke patient support programme
Listen to Nurse Manager Jenny Fleming, Associate Professor in Inflammatory Skin Diseases Miriam Wittmann and Hospital Pharmacist Anusha Patel discuss the benefits of You First as a bespoke patient support programme.
CRP, C-reactive protein; DMARD, disease-modifying anti-rheumatic drug; MRI, magnetic resonance imaging; MTX, methotrexate; NSAID, non-steroidal anti-inflammatory drug.